Chinese pharmaceutical company, YC HEC Changjiang Pharma was attacked by short-seller, Emerson Analytics, in April 2022. The main allegations concerned the precarious financial position of the YC HEC’s ultimate parent, SZ HEC. The short-seller claimed YC HEC had bought assets at inflated prices from its parent. It set a price target of HK$3.29/share, with downside of 30%. YC HEC did not respond to the report; its shares have risen more than 40% since its publication. The allegations against YC HEC are unproven.
Last updated May 2023